Alembic Pharmaceuticals said it has received US Food & Drug Administration (USFDA)'s final approval for Travoprost ophthalmic solution USP, 0.004%.
Alembic Pharmaceuticals (Alembic) on Tuesday announced that the approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product (RLD), Travatan Ophthalmic Solution, 0.004%, of Alcon Pharmaceuticals (Alcon).Travoprost Ophthalmic Solution USP, 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Alembic has a cumulative total of 110 ANDA approvals (97 final approvals and 13 tentative approvals) from USFDA.
Alembic Pharmaceuticals gained 1.07% to Rs 546.15. The stock trades below its 50 days simple moving average placed at 554.05, this level will act as a resistance in near term. The stock trades above its 100 days moving average placed at 534.51, this level will act as support in near term.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
